Now, this won't come as too much of a surprise to Eli Lilly and its peers. A few weeks ago, the company's CEO, David Ricks, ...

The stock should perform well beyond 2030 thanks to its impressive innovative abilities. With a constellation of ...

Eli Lilly and Purdue University expand their partnership with a $250 million investment to advance pharmaceutical innovation ...

Some of the bankrupt company’s closest rivals, newer telehealth firms, face a new challenge of their own as federal ...

Eli Lilly and Company (NYSE: LLY) and Purdue University announced Friday (May 9) a significant expansion of their ...

We recently published a list of the Best Income Stocks to Invest in Now. In this article, we are going to take a look at ...

The investment over the next eight years could be the largest ever industry-academic agreement of its kind in the U.S., the ...

Social media’s favorite grandma opens up about Alzheimer’s awareness, her wellness secrets, and the joy of keeping life ...

Eli Lilly and Co. and Purdue University on Friday announced an expanded collaboration agreement, with the Indianapolis ...

The big pharma will spend up to $250 million over the next eight years of the collaboration. Elsewhere, CRISPR Therapeutics unveiled new data and Vivo Capital raised funds.

Eli Lilly and Purdue University are expanding their partnership to improve drug discovery and manufacturing with a commitment of up to $250 million.

Learn more about whether BioCryst Pharmaceuticals, Inc. or Merus N.V. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.